Palantir Technologies (NASDAQ:PLTR | PLTR Price Prediction) shares are bucking the broader tech rally today, declining 5% to $143. That’s a notable disconnect from the NASDAQ 100, as the Invesco QQQ Trust (NASDAQ:QQQ) is up 3% on the session.
The paradox here is real. Palantir posted some of the most impressive growth numbers in enterprise software last quarter, yet the stock can’t seem to shake two persistent headwinds: a valuation that remains extraordinarily stretched and growing regulatory scrutiny in the United Kingdom. Today, those concerns are winning.
Valuation Concerns Keep Pressure On
The core tension for Palantir Technologies right now is that the growth story is genuinely spectacular. Q4 2025 revenue came in at $1.406 billion, up 70% year-over-year, while full-year 2025 revenue reached $4.475 billion, growing 56.18% year-over-year. Net income for the full year surged 251.59% year-over-year to $1.625 billion. The growth trajectory here is exceptional by any measure.
Yet the valuation attached to that growth is what’s giving investors pause. Palantir stock’s P/E ratio stands at 261x, and even with strong forward guidance, that multiple demands near-perfection in execution. The trailing P/E ratio sits at 238x and the price-to-sales ratio is 80.2x, both figures that reflect a market pricing in years of exceptional growth before a single dollar of margin compression is tolerated.
Wall Street analysts remain broadly bullish. The consensus analyst price target on PLTR stock is $185.25, with 16 buy ratings, 10 holds, and 2 sells. Individual targets range from $180 to $255, well above today’s price. However, the market isn’t following those targets, suggesting that even confident analysts haven’t fully resolved the valuation skepticism among institutional investors.
Palantir Technologies shares were down 15.57% year-to-date heading into today’s session. That context matters. The stock has been under pressure for months, and today’s drop adds to a pattern of compression even as the underlying business accelerates. For investors curious about where the stock could head over a longer horizon, our Palantir stock price prediction looking out to 2030 offers a useful framework for thinking through the bull and bear scenarios.
UK Regulatory Scrutiny Adds an Overhang
Palantir Technologies’ operations in public health and defense in the UK are under regulatory and ethical scrutiny, and that’s weighing on investor sentiment today. The concern centers on how Palantir’s AI-driven platforms are being used in sensitive government and healthcare contexts, and whether those deployments could face contract restrictions or public backlash that limits future revenue in the region.
Granted, Palantir Technologies has flagged this risk category for some time. Palantir’s own filings flag “issues raised by use of artificial intelligence in platforms” as a key risk factor, alongside macroeconomic and geopolitical events. The UK scrutiny brings that abstract filing language into sharp focus, and investors are repricing the stock accordingly today.
Partnership Positives and Insider Context
Palantir has partnered with LG Corp to advance AI commercialization in robotics and enterprise solutions, a deal that strengthens its positioning in manufacturing AI. That’s a genuine long-term positive, though it hasn’t been enough to offset today’s valuation and regulatory pressures.
On the insider front, in March 2026, insiders executed 10 stock sales totaling $292.1 million, with Peter Thiel accounting for more than 98% of that transaction value. Thiel’s sales occurred across six tranches on March 2, with share prices ranging from $140.97 to $146.80. The multi-tranche, single-day execution pattern is consistent with a pre-planned 10b5-1 program rather than any reactive signal about the company’s prospects.
What to Watch
The prediction markets are assigning 99.4% probability to PLTR stock closing down today, so a reversal before the bell looks unlikely. The more important question is whether this valuation compression stabilizes near the 50-day moving average of $146.55 or continues lower toward the 52-week low of $84.14.
Watch for whether any further clarity emerges on the UK regulatory situation, and keep an eye on how institutional holders respond to a stock that’s now trading well below analyst consensus. The growth story hasn’t changed, and for Palantir stock, the valuation debate remains unresolved.
Top Gaining Stocks
Top Losing Stocks